NCT07428967 AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function
| NCT ID | NCT07428967 |
| Status | Recruiting |
| Phase | — |
| Sponsor | St. Josefs-Hospital Wiesbaden GmbH |
| Condition | Atrial Fibrillation |
| Study Type | INTERVENTIONAL |
| Enrollment | 86 participants |
| Start Date | 2026-02-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 86 participants in total. It began in 2026-02-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
AVA CONDUCT is a prospective, multicenter, randomized study with single blinding, comparing left bundle branch area (LBBA) pacing with right ventricular (RV) pacing following AV node ablation in terms of clinical, functional, and electrophysiological outcomes. The primary hypothesis is that pacing-induced cardiomyopathy, defined as a decrease in LVEF by 10% or more from baseline to an absolute value below 50%, occurs significantly more frequently in patients receiving RV pacing compared with LBBA pacing. Secondarily, LBBA pacing is expected to maintain comparable procedural safety while providing better cardiac function, resulting in improved quality of life and functional capacity compared with conventional RV pacing.
Eligibility Criteria
Inclusion Criteria: 1. History of symptomatic AF (EHRA IIb - IV) despite guideline-indicated medical or interventional therapy 2. Preserved LVEF (≥ 50%, assessed by echocardiography, Simpson's biplane method) 3. AV node ablation scheduled independently of possible study participation 4. Age ≥ 18 years 5. Consent capacity Exclusion Criteria: 1. Impaired LVEF (\< 50%) 2. Pre-implanted pacemaker 3. Contraindication for pacemaker implantation or AV node ablation (see chapter 5.3 for details) 4. High grade (III°) left cardiac valvular disease 5. Surgical coronary revascularization (within the last 30 days) or current triple therapy after stent PCI 6. Body-mass-index \> 40 kg/m2 7. Pregnancy 8. Inability to give written informed consent 9. Life expectancy \< 12 months
Frequently Asked Questions
Who can join the NCT07428967 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07428967 currently recruiting?
Yes, NCT07428967 is actively recruiting participants. Visit ClinicalTrials.gov or contact St. Josefs-Hospital Wiesbaden GmbH to inquire about joining.
Where is the NCT07428967 trial being conducted?
This trial is being conducted at Hagen, Germany, Wiesbaden, Germany.
Who is sponsoring the NCT07428967 clinical trial?
NCT07428967 is sponsored by St. Josefs-Hospital Wiesbaden GmbH. The trial plans to enroll 86 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.